Brief: Royalty Pharma Says Co And Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement For New Intravesical Gene Therapy Adstiladrin®

Royalty Pharma

24/08/2023 06:17

Aug 24 (Reuters) - Royalty Pharma PLC  RPRX.O :
    * AND FERRING PHARMACEUTICALS ENTER INTO US $500 MILLION
ROYALTY
AGREEMENT FOR NEW INTRAVESICAL GENE THERAPY ADSTILADRIN®
(NADOFARAGENE FIRADENOVEC-VNCG)
    * ROYALTY PHARMA TO PAY FERRING $300 MILLION UPFRONT AND A
POTENTIAL $200 MILLION MILESTONE PAYMENT IN EXCHANGE FOR
ROYALTIES
    * ROYALTY PHARMA IS ACQUIRING A 5.1% PERCENTAGE ROYALTY ON
NET
SALES OF ADSTILADRIN IN UNITED STATES
    * ROYALTY IS EXPECTED TO END IN EARLY TO MID-2030S
    * ROYALTY IS EXPECTED TO END IN EARLY TO MID-2030S

Source text for Eikon:  ID:nBw2v4b2ba 
Further company coverage:  RPRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))